A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization

被引:38
作者
Ahmed, A
Thompson, J
Emiliusen, L
Murphy, S
Beauchamp, RD
Suzuki, K
Alemany, R
Harrington, K
Vile, RG
机构
[1] Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA
[3] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37235 USA
[4] Inst Catala Oncol, Barcelona, Spain
[5] Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England
关键词
D O I
10.1038/nbt835
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The expression of various proteins associated with rapid responses to inflammation and/or proliferation can be controlled at the level of mRNA stability. Because tumor cells continually recapitulate intracellular programs of proliferation, we have used tumor cell-selective stabilization of mRNA as a means to control therapeutic gene expression. We describe an adenoviral vector that is conditionally replication competent in which expression of the essential adenoviral early region 1A (E1A) gene is regulated by ligation to the 3 untranslated region (UTR) of PTGS2 (also known as COX2), the gene encoding prostaglandin-endoperoxide synthase 2, allowing activated RAS/P-MAPK-specific stabilization of its mRNA. Induction of activated RAS supports replication, whereas matched cells in which activated RAS/P-MAPK is not expressed are very poor substrates for viral replication both in vitro and in vivo. Further tumor-targeting strategies will also be required to prevent viral replication at extratumoral sites where PTGS2 is normally induced. Many different genes contain 3 UTRs that control selective mRNA stability under different physiological, pathological and tumor-associated conditions. Therefore, generating tumor selectivity at the level of mRNA stability is a strategy with broad potential applicability in vector design.
引用
收藏
页码:771 / 777
页数:7
相关论文
共 48 条
[1]   Replicative adenoviruses for cancer therapy [J].
Alemany, R ;
Balagué, C ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 2000, 18 (07) :723-727
[2]   COX-2 and cancer: a new approach to an old problem [J].
Bakhle, YS .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) :1137-1150
[3]  
BAUER SR, 1989, ONCOGENE, V4, P615
[4]   Replication-selective viruses for cancer therapy [J].
Biederer, C ;
Ries, S ;
Brandts, CH ;
McCormick, F .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (03) :163-175
[5]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[6]  
Blackburn RV, 1998, CANCER RES, V58, P1358
[7]   Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade [J].
Brook, M ;
Sully, G ;
Clark, AR ;
Saklatvala, J .
FEBS LETTERS, 2000, 483 (01) :57-61
[8]   Many actions of cyclooxygenase-2 in cellular dynamics and in cancer [J].
Cao, Y ;
Prescott, SM .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 190 (03) :279-286
[9]   IDENTIFICATION OF A COMMON NUCLEOTIDE-SEQUENCE IN THE 3'-UNTRANSLATED REGION OF MESSENGER-RNA MOLECULES SPECIFYING INFLAMMATORY MEDIATORS [J].
CAPUT, D ;
BEUTLER, B ;
HARTOG, K ;
THAYER, R ;
BROWNSHIMER, S ;
CERAMI, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (06) :1670-1674
[10]  
CHEN CYA, 1995, MOL CELL BIOL, V15, P5777